The Board of Directors of Metropolis Healthcare has approved an interim dividend of ₹4 per equity share with a face value of ₹2. The record date for determining shareholders eligible for the dividend is November 11, 2025. The dividend payout will occur within 30 days of the declaration. Additionally, the board reviewed and approved the unaudited financial results for Q2 2025-26.
Interim Dividend Declared
The Board has declared an interim dividend of ₹4 per share, on equity shares with a face value of ₹2 each. The dividend will be paid to shareholders on record as of November 11, 2025. The payout is scheduled within 30 days of the declaration date.
Financial Highlights: Q2 2025-26
Metropolis Healthcare reported the following key figures for the quarter ended September 30, 2025 (Q2 2025-26):
- Revenue from operations: ₹355.71 million
- Total Income: ₹358.23 million
- Profit before tax: ₹62.11 million
- Profit after tax: ₹46.63 million
The results reflect both standalone and consolidated financial performance, showcasing overall growth and profitability.
Business Updates
Metropolis Healthcare has also been active in strategic business development, including acquisition and expansion. Notably, there have been two acquisitions by subsidiaries:
- Acquisition of Dr. Ahujas’ Pathology & Imaging Centre (DAPIC) through Dapic Metropolis Healthcare Private Limited.
- Acquisition of Dr. Ashok Kumar Sharma’s Scientific Pathology by Scientific Metropolis Pathology Private Limited.
- Acquisition of Dr. Rajendra Sadashiv Patil’s Ambika Pathology Laboratory
These acquisitions are aimed at expanding Metropolis Healthcare’s reach and service offerings across different regions.
Source: BSE
